Privi Speciality Chemicals delivered robust financial performance in the June 2026 quarter, with consolidated net profit attributable to owners surging 35.8% to ₹84.21 crore compared to ₹61.93 crore in the corresponding quarter of the previous year. According to the latest unaudited financial results approved by the Board of Directors on July 30, 2026, this significant profit growth demonstrates the company's operational efficiency and strong performance in its single operating segment, Aroma Chemical. The standalone net profit also increased 22.7% to ₹84.26 crore, reflecting consistent performance across both standalone and consolidated operations. The overall consolidated profit for the period, including non-controlling interest, stood at ₹82.84 crore compared with ₹57.55 crore in Q1 FY26, with the difference arising due to losses attributable to non-controlling interests during the quarter.
The company's consolidated revenue from operations increased 19.2% to ₹666.22 crore in Q1 FY2026, up from ₹558.81 crore in the same period last year. As reported in the latest financial results, standalone revenue grew modestly by 6.0% to ₹60.06 crore compared to the previous year. The total income rose 20% to ₹681.42 crore from ₹567.80 crore year-on-year, with standalone other income increasing significantly to ₹14.62 crore from ₹8.31 crore in the corresponding quarter last year. However, compared with Q4 FY26, the company reported a sequential decline in revenue and profit, with revenue decreasing from ₹721.52 crore in Q4 FY26 to ₹666.22 crore in Q1 FY27, while net profit attributable to owners fell from ₹93.70 crore to ₹84.21 crore quarter-on-quarter. The divergence between standalone and consolidated revenue growth highlights the impact of subsidiaries on overall top-line performance, with international or subsidiary operations currently driving primary volume growth for the group.
EBITDA grew 15.2% to ₹152 crore from ₹132 crore year-on-year, though the EBITDA margin contracted 77 basis points to 22.86% from 23.63% in the previous year. According to the latest financial data, this margin pressure indicates that operating costs grew slightly faster than EBITDA during the quarter. Profit before tax increased 39.7% to ₹113.37 crore from ₹81.18 crore in the corresponding quarter of the previous financial year, demonstrating strong bottom-line performance despite margin challenges. The earnings per share (EPS) for standalone operations was ₹21.57 compared to ₹21.56 in the previous year, while consolidated EPS stood at ₹21.56 with a 36.2% increase year-on-year. Despite the margin pressure, Privi maintained an operating margin above 22%, while absolute EBITDA continued to record double-digit growth.
The company's cost structure showed mixed trends during the quarter. Cost of materials consumed increased 25.2% standalone and 29.8% consolidated, reflecting higher raw material costs and input cost pressures in the aroma chemical segment. Cost of materials consumed rose to ₹396.88 crore compared with ₹305.76 crore in the corresponding quarter last year. Employee benefit expenses increased to ₹29.91 crore from ₹27.39 crore, while power and fuel expenses climbed to ₹45.94 crore from ₹38.89 crore. However, other expenses declined to ₹66.51 crore from ₹85.22 crore, partly supporting overall profitability. Finance costs dropped significantly to ₹16.74 crore compared with ₹23.66 crore in Q1 FY26, with depreciation and amortisation expenses also edging higher to ₹37.36 crore from ₹36.21 crore. The reduction in borrowing-related expenses helped profit before tax grow considerably faster than EBITDA.
Motilal Oswal has recommended a buy rating on Privi Speciality Chemicals with a target price of ₹4,400 in its research report dated July 31, 2026. The brokerage firm projects a CAGR of 25%/28%/36% in revenue/EBITDA/adjusted PAT over FY26-28E and maintains its BUY rating based on 30x FY28E EPS. The company delivered healthy revenue growth of 19% YoY to ₹1.5 billion in Q1 FY27, driven by healthy volume and realizations, with EBITDA growing 15% YoY supported by lower other operating expenses driven by efficiency initiatives and stringent cost controls. While the 77-basis-point contraction in EBITDA margin remains a key monitorable, the company's strong volume growth and effective cost management support the positive outlook. The Board had previously recommended a final dividend of ₹10 per equity share for the financial year ended March 31, 2026, aggregating to ₹39.06 crore, subject to shareholder approval at the 41st annual general meeting.
